Senguttuvan, R.N.;                     Wei, C.;                     Raoof, M.;                     Dellinger, T.H.;                     Wang, E.W.    
        Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma. J. Clin. Med. 2023, 12, 3839.
    https://doi.org/10.3390/jcm12113839
    AMA Style
    
                                Senguttuvan RN,                                 Wei C,                                 Raoof M,                                 Dellinger TH,                                 Wang EW.        
                Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma. Journal of Clinical Medicine. 2023; 12(11):3839.
        https://doi.org/10.3390/jcm12113839
    
    Chicago/Turabian Style
    
                                Senguttuvan, Rosemary Noel,                                 Christina Wei,                                 Mustafa Raoof,                                 Thanh H. Dellinger,                                 and Edward Wenge Wang.        
                2023. "Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma" Journal of Clinical Medicine 12, no. 11: 3839.
        https://doi.org/10.3390/jcm12113839
    
    APA Style
    
                                Senguttuvan, R. N.,                                 Wei, C.,                                 Raoof, M.,                                 Dellinger, T. H.,                                 & Wang, E. W.        
        
        (2023). Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma. Journal of Clinical Medicine, 12(11), 3839.
        https://doi.org/10.3390/jcm12113839